Primarily intended for administration to postmenopausal women, Exemestane assumes a pivotal role in the management of hormone receptor-positive early-stage breast cancer, particularly in the context of adjuvant therapy following a regimen of two to three years of Tamoxifen treatment. The gene discussed is NR4A1; the disease is breast carcinoma.